Cardlytics (NASDAQ:CDLX) Earns “Hold” Rating from Needham & Company LLC

Cardlytics (NASDAQ:CDLX)‘s stock had its “hold” rating reissued by research analysts at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports.

A number of other brokerages have also commented on CDLX. Evercore ISI assumed coverage on shares of Cardlytics in a report on Friday, October 11th. They set an “in-line” rating and a $4.00 price objective on the stock. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.92.

Cardlytics Stock Performance

NASDAQ CDLX opened at $3.16 on Friday. Cardlytics has a 1-year low of $2.76 and a 1-year high of $20.52. The company has a 50 day moving average of $3.69 and a 200-day moving average of $4.53. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm has a market cap of $160.59 million, a price-to-earnings ratio of -0.52 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The firm had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business’s revenue was down 15.1% on a year-over-year basis. During the same period last year, the firm posted ($0.26) EPS. On average, equities analysts forecast that Cardlytics will post -1.52 earnings per share for the current fiscal year.

Insider Transactions at Cardlytics

In other Cardlytics news, CFO Alexis Desieno sold 25,118 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,007 shares of company stock worth $251,297 in the last quarter. 4.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Check Capital Management Inc. CA boosted its position in Cardlytics by 10.4% during the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock worth $162,000 after acquiring an additional 4,775 shares during the last quarter. BNP Paribas Financial Markets lifted its position in shares of Cardlytics by 32.1% in the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock worth $63,000 after purchasing an additional 4,796 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Cardlytics by 38.2% during the fourth quarter. SG Americas Securities LLC now owns 19,490 shares of the company’s stock worth $72,000 after purchasing an additional 5,392 shares during the last quarter. Creative Planning grew its position in Cardlytics by 35.4% in the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares in the last quarter. Finally, Tallon Kerry Patrick acquired a new stake in Cardlytics in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.